Hydroxychloroquine and visual screening in a rheumatology outpatient clinic
Hydroxychloroquine and visual screening in a rheumatology outpatient clinic
复制标题
DOI：
10.1136/ard.56.3.188
复制
发表时间：
1997-03-01
影响因子：
27.4
通讯作者：
Grierson, DJ
中科院分区：
文献类型：
--
作者：
Grierson, DJ
目的 - 回顾 10 年来与服用羟氯喹的患者进行视力筛查相关的数据。方法 - 在基线视力评估之后，对 758 名服用羟氯喹的患者每隔六个月进行一次眼科监测。这包括矫正视力、使用红色阿姆斯勒方格进行中心视野筛查、裂隙灯检查和检影镜检查。结果 - 尽管有 12 名患者报告视力障碍，但没有患者因视网膜毒性而出现视力障碍。这与四名患者的眼肌不平衡有关。在其余的情况下，没有任何眼部发现可直接归因于羟氯喹。十名患者在使用红色阿姆斯勒网格进行测试时报告了缺陷。没有一个与视网膜毒性有关。 7 名患者出现角膜药物沉积，在停止或减少羟氯喹剂量后清除。结论 - 研究结果支持以下观点：接受羟氯喹的患者在基线眼科检查后，如果每日剂量低于 6.5 mg kg(-1) 且累积剂量低于 200 g，则不需要定期进行眼科筛查。
Objective - To review 10 years' data relating to visual screening of patients taking hydroxychloroquine.Methods - Following baseline visual assessment, ophthalmic monitoring was carried out at six monthly intervals on 758 patients while on hydroxychloroquine. This consisted of corrected visual acuity, central field screening with a red Amsler grid, slit lamp examination, and retinoscopy.Results - None of the patients suffered visual impairment from retinal toxicity, though 12 reported visual disturbance. This was related to ocular muscle imbalance in four. In the remainder, none of the ocular findings was directly attributable to hydroxychloroquine. Ten patients reported defects when tested with a red Amsler grid. None was related to retinal toxicity. Seven patients developed corneal drug deposits which cleared on stopping or reducing the dose of hydroxychloroquine.Conclusions - The findings support the view that following baseline ophthalmic examination for patients receiving hydroxychloroquine, regular ophthalmic screening is not required if the daily dose is less than 6.5 mg kg(-1) and the cumulative dose is less than 200 g.